1-methyl-1H-indole-5-sulfonyl chloride → 5-(3,4-Dimethoxyphenyl)-4,4-dimethyl-2-{1-[(1-methyl-1H-indol-5-yl)sulfonyl]piperidin-4-yl}-2,4-dihydro-3H-pyrazol-3-one

HRID 524237

反応式

HRID 524237 の反応式
Cl.[CH3:2][O:3][C:4]1[CH:5]=[C:6]([C:12]2[C:13]([CH3:25])([CH3:24])[C:14](=[O:23])[N:15]([CH:17]3[CH2:22][CH2:21][NH:20][CH2:19][CH2:18]3)[N:16]=2)[CH:7]=[CH:8][C:9]=1[O:10][CH3:11].[CH3:26][N:27]1[C:35]2[C:30](=[CH:31][C:32]([S:36](Cl)(=[O:38])=[O:37])=[CH:33][CH:34]=2)[CH:29]=[CH:28]1>>[CH3:2][O:3][C:4]1[CH:5]=[C:6]([C:12]2[C:13]([CH3:25])([CH3:24])[C:14](=[O:23])[N:15]([CH:17]3[CH2:22][CH2:21][N:20]([S:36]([C:32]4[CH:31]=[C:30]5[C:35](=[CH:34][CH:33]=4)[N:27]([CH3:26])[CH:28]=[CH:29]5)(=[O:37])=[O:38])[CH2:19][CH2:18]3)[N:16]=2)[CH:7]=[CH:8][C:9]=1[O:10][CH3:11]

参加物

3

実験手順

The title compound is prepared analogously as described for GP1 using 5-(3,4-dimethoxyphenyl)-4,4-dimethyl-2-(piperidin-4-yl)-2,4-dihydro-3H-pyrazol-3-one (compound B1) and 1-methyl-1H-indole-5-sulfonyl chloride as starting compounds. The crude product is purified by crystallization from EA and diethyl ether to yield the title compound.

後処理

  1. customThe title compound is prepared analogously
  2. customThe crude product is purified by crystallization from EA and diethyl ether

出典と根拠

ORDレコード
ord-13500ae2e0bd4222bf1a9004c64e6842
出典データセット
uspto-grants-2016_05
特許番号
US09340522B2

関連ノート

読み込み中…